China's biopharma industry: the small molecule renaissance in rare diseases
Approvals for innovator small molecules treating rare diseases in China rose by 22% from 2020 to 2022, giving hope to rare disease patients.
National Rare Diseases Registry System Method Development Software For The Pharmaceutical Industry National Medical Products Administration Drugs Intelligence Database Drug Database Analysis Techniques
Source: pharmaceutical-technology.com